<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169802</url>
  </required_header>
  <id_info>
    <org_study_id>SCT-201</org_study_id>
    <nct_id>NCT04169802</nct_id>
  </id_info>
  <brief_title>Study Evaluating Retinal Health Monitoring System Visual Acuity Module.</brief_title>
  <official_title>An Observational, Non-Significant Risk Study Of The Retinal Health Monitoring System (RHMS) - Visual Acuity Module - In Normal Patients And Patients With Neovascular Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kubota Vision Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kubota Vision Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the performance and usability of the RHMS Visual Acuity Module.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 510(k)-enabling study is designed to assess the performance and usability of the RHMS
      Visual Acuity Module in normal patients and patients with neovascular AMD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">April 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the repeatability of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart</measure>
    <time_frame>1 day</time_frame>
    <description>To determine the precision (repeatability and reproducibility) of corrected near visual acuity (CNVA) measured by the RHMS Visual Acuity Module and an in-clinic, near logarithmic Sloan Letter chart (Reference Chart).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the reproducibility of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the agreement of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agreement of CNVA measured by the RHMS Visual Acuity Module and the Reference Chart</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the usability of the RHMS Visual Acuity Module</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Normal subjects</arm_group_label>
    <description>Age ≥ 50 years, Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with neovascular AMD</arm_group_label>
    <description>Age ≥ 50 years, History of neovascular age-related macular degeneration, in the study eye, Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Retinal Health Monitoring System Visual Acuity Module</intervention_name>
    <description>Assessment of corrected near visual acuity</description>
    <arm_group_label>Normal subjects</arm_group_label>
    <arm_group_label>Subjects with neovascular AMD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sloan letter, logarithmic near visual acuity chart (Reference Chart)</intervention_name>
    <description>Assessment of corrected near visual acuity</description>
    <arm_group_label>Normal subjects</arm_group_label>
    <arm_group_label>Subjects with neovascular AMD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged ≥ 50 years, with a normal central macula or with neovascular AMD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1 - Normal subjects

          1. Age ≥ 50 years

          2. Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the
             study eye

          3. Able to perform self-testing with the Visual Acuity Module of the RHMS after training

          4. Able and willing to give informed consent

        Cohort 2 - Subjects with neovascular AMD

          1. Age ≥ 50 years

          2. History of neovascular age-related macular degeneration, in the study eye

          3. Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye

        Exclusion Criteria:

        Cohort 1 - Normal subjects

          1. History of ophthalmic disease resulting in decrease in visual acuity per the
             Investigator, in the study eye

          2. Use of any investigational drug in the past 30 days, or investigational,
             interventional device in the past 60 days

        Cohort 2 - Subjects with neovascular AMD

          1. History of geographic atrophy or macular atrophy within the central 3 mm of the
             macula, in the study eye

          2. History of macular hole in the study eye

          3. Use of any investigational drug in the past 30 days, or investigational,
             interventional device in the past 60 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Gregory, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kubota Vision Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>visual acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

